The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 40.00
Ask: 41.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.50%)
Open: 40.50
High: 40.50
Low: 39.20
Prev. Close: 40.50
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update re Revolving Credit Facility

13 Mar 2023 07:00

RNS Number : 6624S
Venture Life Group PLC
13 March 2023
 

13th March 2023

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Company")

Update regarding Revolving Credit Facility

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces an update regarding its Revolving Credit Facility ("RCF"), in the light of the recent events at Silicon Valley Bank.

The RCF, which provides VLG with available borrowings of up to £30 million is co-ordinated and managed by VLG's main relationship bank, Santander UK plc ("Santander"), and Silicon Valley Bank UK also participates in the RCF.

In light of the recent events at Silicon Valley Bank, the Group wants to clarify the nature of its relationship with Silicon Valley Bank UK ("SVB"):

· Neither VLG nor its subsidiaries (the "Group") has any deposits with SVB either in the UK or the USA. The Group is therefore not dependent on SVB to make payments to third parties and there are no funds of the Group at risk as a result of any insolvency of SVB.

· SVB is a lender under the RCF, and provides 50% of the funds drawn under the facility.

· The anticipated insolvency of SVB will have no impact on the term of the RCF which is not due for renewal until June 2024; and will not result in any acceleration of the repayments due by VLG under the RCF.

The RCF contains a mechanic under which Santander may take over the SVB portion of the RCF (and also allows for another lender to participate in the RCF). The Group has commenced discussions with Santander in relation to Santander doing this, and those initial discussions have been positive. Santander have indicated they remain fully supportive of VLG and of VLG's plans to commence a refinance of the RCF given the expiry in June 2024. Those plans will now be accelerated.

As set out in the Group's trading update on 31st January 2023, Group leverage2 at 31st December 2022 was in the region of 1.4x net debt to Adjusted EBITDA1 (31st December 2021: 0.4x) reflecting the impact of the recent acquisition of HL Healthcare Limited (including the Earol brand).

Group leverage is expected to fall in 2023 to 1.0x or lower by the end of 2023, due to the cash generative nature of the business, now including the highly cash generative Earol brand.

The Group's audited results for the year ended 31st December 2022 are expected to be published around the end of the first quarter of 2023 and the Group expects that these will be at least in line with market expectations. Trading momentum has continued in the first two months of the current year and the Group has seen strong cash generation as expected which has reduced Group leverage to 1.3x net debt to Adjusted EBITDA. Liquidity is sufficient and stable, and the Board do not envisage any impact or risk to the business arising from events at SVB.

Jerry Randall, Chief Executive Officer, commented: "The Group has had a strong start to 2023 and seen very good cash generation off the back of strong trading in Q4 2022, and is trading in line with our expectations. The acquisiton of HL Healthcare Limited is integrating well into the Group and contributing positively to EBITDA and cashflow. As stated the Group has no deposits with Silicon Valley Bank, and so is not exposed to any deposit risk. With the strong results in 2022, low Group leverage and strong start to 2023, the Board is confident that it could comfortably refinance the Silicon Valley Bank portion of its RCF either at the renewal in June 2024 or before."

 

1 Adjusted EBITDA is EBITDA before deduction of exceptional items and share based payments

2 Group leverage calculated as net debt (excluding finance leases) and using proforma Adjusted EBITDA on a trailing 12-month basis

 

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker)

 

+44 (0) 20 7397 8900

Michael Johnson/Russell Kerr (Sales)

Stephen Keys/Camilla Hume (Corporate Finance)

 

 

Singer Capital markets (Joint Broker)

 

+44 (0) 20 7496 3000

Jonathan Dighe (Sales)

Shaun Dobson/Alaina Wong (Corporate Finance)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSFMESEEDSESD
Date   Source Headline
1st Mar 201612:07 pmRNSResult of General Meeting and Issue of Equity
18th Feb 201610:20 amRNSDirectorate Change
12th Feb 20165:38 pmRNSCircular Publication & Notice of General Meeting
12th Feb 201612:11 pmRNSResults of Placing to Partially Fund Acquisition
12th Feb 20167:00 amRNSProposed Placing and issue of Convertible Bonds
13th Jan 20167:00 amRNSProduct Launch
23rd Dec 20157:38 amRNSTrading Update
29th Sep 20157:00 amRNSInterim Results
9th Sep 20157:00 amRNSNotice of Results
9th Jul 20157:00 amRNSPre-Close Trading Statement
10th Jun 201511:41 amRNSAGM Statement
9th Jun 20157:00 amRNSStrategic Development and Commercial Alliance
22nd May 20157:00 amRNSPDMR Shareholding
15th Apr 20157:00 amRNS2014 Annual Report and Dividend Timetable
25th Mar 20157:00 amRNSFinal Results
16th Mar 20157:00 amRNSSale of trademarks: manufacturing agreement signed
26th Jan 20157:00 amRNS30-year exclusive distribution deal signed
9th Dec 20147:00 amRNSBenecol Supplement Capsule Sale Malta
4th Dec 201411:54 amRNSHolding(s) in Company
28th Nov 20147:00 amRNSShare Placing
19th Nov 20147:00 amRNSAppointment of Nominated Adviser and Broker
10th Oct 20147:00 amRNSDirector's Dealings
8th Oct 20147:00 amRNSDirector Dealings
6th Oct 20147:00 amRNSDirectors' Dealings
1st Oct 20147:00 amRNSInvestor Forum
29th Sep 20147:00 amRNSInterim Results
23rd Sep 20147:00 amRNSNew distribution agreements
5th Sep 20147:00 amRNSNotice of Interim Results
6th Aug 20147:00 amRNSNew Product Development and Board Change
7th Jul 20147:00 amRNSNew distribution agreement signed
30th Jun 201412:09 pmRNSAGM Statement
30th Jun 20147:00 amRNSTotal Voting Rights
25th Jun 20147:00 amRNSNew distribution agreements signed
17th Jun 20147:00 amRNSAppointment of Non-Executive Director
13th Jun 20149:44 amRNSHolding(s) in Company
5th Jun 20147:01 amRNSIssue of new shares
5th Jun 20147:00 amRNSFinal Results
23rd Apr 20147:00 amRNSNew Distribution Agreement
28th Mar 20148:00 amRNSAdmission to AIM and Acquisition of Biokosmes Srl

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.